No Data
No Data
No Data
No Data
No Data
Insiders With Their Considerable Ownership Were the Key Benefactors as Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Touches CN¥22b Market Cap
Key Insights Insiders appear to have a vested interest in Nanjing King-Friend Biochemical PharmaceuticalLtd's growth, as seen by their sizeable ownership The top 3 shareholders own 68% of the compan
Simply Wall StMay 5 20:58 ET
NKFPharma Gets Nod to Register New Cancer Treatment
Jianjin Pharmaceutical, a unit of Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707), received the drug registration certificate from China's National Medical Products Administration for bort
MT NewswiresMay 1 02:32 ET
Jianyou Co., Ltd. (603707.SH): 2023 net profit - $189 million
On April 27, Gelonghui Co., Ltd. (603707.SH) released its 2023 annual report. During the reporting period, the company achieved operating revenue of 3,931 billion yuan, an increase of 5.89% over the previous year. Among them, pharmaceuticals achieved revenue of 2,772 billion yuan, accounting for 70.50%; APIs achieved revenue of 997 million yuan, accounting for 25.37%. Affected by lower order prices and inventory deductions, the company achieved net profit of $189 million and basic earnings per share of $0.12.
Gelonghui FinanceApr 26 23:38 ET
Jianyou Co., Ltd. (603707.SH) announced first-quarter results, net profit of 177 million yuan, a year-on-year decrease of 46.68%
According to Zhitong Finance App News, Jianyou Co., Ltd. (603707.SH) released its report for the first quarter of 2024. The company's revenue was 1.04 billion yuan, down 23.19% year on year; net profit attributable to shareholders of listed companies was 177 million yuan, down 46.68% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 171 million yuan, down 48.12% year on year; basic earnings per share were 0.11 yuan/share.
Zhitong FinanceApr 26 12:59 ET
Insufficient Growth At Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Hampers Share Price
With a price-to-earnings (or "P/E") ratio of 19.2x Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) may be sending bullish signals at the moment, given that almost half of all com
Simply Wall StApr 8 20:01 ET
Is Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Nanjing King-Friend Biochemical PharmaceuticalLtd's estimated fair value is CN¥10.09 based on 2 Stage Free Cash Flow to Equity Current share price of CN¥12.15 suggests Nanjing King-Frie
Simply Wall StMar 18 02:10 ET
No Data
No Data